A Phase I/II Open-Label Study of ECT-001-Expanded Cord Blood Transplantation in Pediatric and Young Adult (<21year) Patients With High-Risk and Very High-Risk Myeloid Malignancies
Latest Information Update: 26 Jun 2024
At a glance
- Drugs Dorocubicel-ExCellThera (Primary) ; Busulfan; Clofarabine; Cyclophosphamide; Fludarabine; Mycophenolate mofetil; Tacrolimus; Thiotepa
- Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Juvenile myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Sponsors ExCellThera
- 15 Feb 2024 Planned End Date changed from 1 Dec 2025 to 1 Jun 2026.
- 15 Feb 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Jun 2026.
- 05 Sep 2023 Planned End Date changed from 1 Jul 2025 to 1 Dec 2025.